Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, provide comprehensive insights on the evolving treatment landscape for patients with HR+ breast cancer and ESR1 mutations.
EP. 1: Testing for ESR1 Mutations in Breast Cancer
Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.
EP. 2: Overcoming Challenges in Biomarker Testing in Breast Cancer
Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.
EP. 3: PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer
Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).
EP. 4: EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer
Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.
EP. 5: The Role of Elacestrant in Breast Cancer
Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.
EP. 6: SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+/HER2- Breast Cancer
Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.
EP. 7: Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 Mutations
Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer